Jon Roffey

Jon Roffey Joined OMass Therapeutics in July 2022 as Vice President, Head of Medicinal Chemistry. Jon has over 20 years’ experience in drug discovery in a wide variety of therapeutic areas including oncology, CNS, and metabolic disorders across a range of therapeutic modalities. Jon joined OMass Therapeutics from Nanna therapeutics, where he was Head of Chemistry, leading a portfolio of mitochondrial targeted programs to treat rare diseases. Prior to that he was Director of Chemistry at Azeria Therapeutics, a company he helped spin-out from the University of Cambridge. Previously, at Cancer Research Technology, he was a Senior Group Leader and at Spirogen, he lead and established the antibody drug conjugate programme, which led to the clinical development of vadastuximab talirine and rovalpituzumab tesirine. He started his Medicinal chemistry career at Vernalis, as a Senior Scientist working on a variety of GPCR targets. Jon has a PhD in Organic Chemistry obtained from the University of Loughborough.